Home / News / US FDA lifts clinical hold on Bharat Biotech's Covid vaccine Covaxin
Back

Bharat Biotech's Covaxin will be evaluated as a Covid vaccine candidate in the United States, the company informed on Saturday. 

Ocugen, Inc announced that the US Food and Drug Administration (FDA) has lifted its clinical hld on the company's investigational new drug application to evaluate the Covid vaccine candidate, BB152, known as Covaxin outside the US, Bharat Biotech said in a statement.

Ocugen is co-developing Bharat Biotech's Covaxin vaccine for Covid in US and Canada.

 

 

 

 

 

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout